Literature DB >> 20036953

Homocysteine, vitamin determinants and neurological diseases.

Riccardo Ientile1, Monica Curro', Nadia Ferlazzo, Salvatore Condello, Daniela Caccamo, Francesco Pisani.   

Abstract

This review focuses on the putative role of hyper-homocysteinemia in the pathogenesis of different diseases affecting the nervous system, including stroke, Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis and amyotrophic lateral sclerosis. However, a firm pathogenic role of homocysteine in these diseases has never been established. Lowering plasma homocysteine levels trough vitamin therapy failed to prevent vascular diseases. Conversely, normalization of hyper-homocysteinemia caused improvement in patients with cognitive impairment. B vitamin deficiency is the main determinant of homocysteine levels. However, it has been hypothesized that homocysteine might be a mere marker of vitamin deficiency or an indicator of disease rather than a risk factor. A more consistent use of thresholds to define deficiency is needed to recommend routine screening, monitoring and supplementation of B vitamins to ameliorate the prognosis of the above mentioned disorders. To date, data are insufficient to firmly establish which one of the hypotheses made is correct and the question concerning the real meaning of hyper-homocysteinemia in the pathology of the nervous system still remains an intriguing medical dilemma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20036953     DOI: 10.2741/s70

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  9 in total

1.  The 894G > T (Glu298Asp) variant in the endothelial NOS gene and MTHFR polymorphisms influence homocysteine levels in patients with cognitive decline.

Authors:  Nadia Ferlazzo; Gaetano Gorgone; Daniela Caccamo; Monica Currò; Salvatore Condello; Francesco Pisani; Fabrizio Vernieri; Paolo Maria Rossini; Riccardo Ientile
Journal:  Neuromolecular Med       Date:  2011-05-24       Impact factor: 3.843

Review 2.  NADPH oxidases: an overview from structure to innate immunity-associated pathologies.

Authors:  Arvind Panday; Malaya K Sahoo; Diana Osorio; Sanjay Batra
Journal:  Cell Mol Immunol       Date:  2014-09-29       Impact factor: 11.530

3.  Toxic effects of mildly elevated homocysteine concentrations in neuronal-like cells.

Authors:  M Currò; A Gugliandolo; C Gangemi; R Risitano; R Ientile; D Caccamo
Journal:  Neurochem Res       Date:  2014-05-28       Impact factor: 3.996

4.  Inhibition of hyperhomocysteinemia-induced inflammasome activation and glomerular sclerosis by NLRP3 gene deletion.

Authors:  Min Xia; Sabena M Conley; Guangbi Li; Pin-Lan Li; Krishna M Boini
Journal:  Cell Physiol Biochem       Date:  2014-08-20

5.  NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia.

Authors:  Justine M Abais; Chun Zhang; Min Xia; Qinglian Liu; Todd W B Gehr; Krishna M Boini; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2012-12-10       Impact factor: 8.401

Review 6.  Hyperhomocysteinemia is an emerging comorbidity in ischemic stroke.

Authors:  Ranjana Poddar
Journal:  Exp Neurol       Date:  2020-12-03       Impact factor: 5.330

Review 7.  Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies.

Authors:  Caterina Tinelli; Antonella Di Pino; Elena Ficulle; Serena Marcelli; Marco Feligioni
Journal:  Front Nutr       Date:  2019-04-24

8.  Association of plasma homocysteine with self-reported sleep apnea is confounded by age: results from the national health and nutrition examination survey 2005-2006.

Authors:  Tushar P Thakre; Manju Mamtani; Shweta Ujaoney; Hemant Kulkarni
Journal:  Sleep Disord       Date:  2011-12-29

Review 9.  Homocysteine Plasmatic Concentration in Brain-Injured Neurocritical Care Patients: Systematic Review of Clinical Evidence.

Authors:  Maria Paola Lauretta; Rita Maria Melotti; Corinne Sangermano; Anneliya Maria George; Rafael Badenes; Federico Bilotta
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.